激素宮內節育器(hormonal intrauterine device)常見者為含孕激素子宮內系統(intrauterine system (IUS) with progestogen),商品名有 Mirena(蜜蕊娜、曼月乐)等,是一种可以释放激素(如屬於孕激素的左炔諾孕酮)的宫内节育器[1],其用途包括避孕、缓解月经过多、预防雌激素替代疗法可能产生的子宫内膜增生等[1]。
完整的禁忌症清單可在世界衛生組織避孕藥物使用醫學適應症標準(Medical Eligibility Criteria for Contraceptive Use)和CDC美國避孕藥物使用醫學適應症標準(United States Medical Eligibility Criteria for Contraceptive Use)中取得[24][49]。
^World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. March 2009, 79 (3): 189–193. PMID 19185671. doi:10.1016/j.contraception.2008.11.004.
^Faundes A, Alvarez F, Brache V, Tejada AS. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. International Journal of Gynaecology and Obstetrics. June 1988, 26 (3): 429–433. PMID 2900174. S2CID 34592937. doi:10.1016/0020-7292(88)90341-4.
^Oelschlager AM, Debiec K, Micks E, Prager S. Use of the Levonorgestrel Intrauterine System in Adolescents With Known Uterine Didelphys or Unicornuate Uterus. Journal of Pediatric and Adolescent Gynecology. 2013, 26 (2): e58. ISSN 1083-3188. doi:10.1016/j.jpag.2013.01.029.
^Schiappacasse V, Díaz S, Zepeda A, Alvarado R, Herreros C. Health and growth of infants breastfed by Norplant contraceptive implants users: a six-year follow-up study. Contraception. July 2002, 66 (1): 57–65. PMID 12169382. doi:10.1016/S0010-7824(02)00319-0.
^Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. February 2002, 65 (2): 129–132. PMID 11927115. doi:10.1016/S0010-7824(01)00302-X.
^Rönnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstetricia et Gynecologica Scandinavica. September 1999, 78 (8): 716–721. PMID 10468065. doi:10.1034/j.1600-0412.1999.780810.x.
Mechanism of action Although the precise mechanism of action is not known, currently available IUCs work primarily by preventing sperm from fertilizing ova.26 IUCs are not abortifacients: they do not interrupt an implanted pregnancy.27 Pregnancy is prevented by a combination of the "foreign body effect" of the plastic or metal frame and the specific action of the medication (copper or levonorgestrel) that is released. Exposure to a foreign body causes a sterile inflammatory reaction in the intrauterine environment that is toxic to sperm and ova and impairs implantation.28,29 The production of cytotoxic peptides and activation of enzymes lead to inhibition of sperm motility, reduced sperm capacite journal and survival, and increased phagocytosis of sperm.30,31… The progestin in the LNg IUC enhances the contraceptive action of the device by thickening cervical mucus, suppressing the endometrium, and impairing sperm function. In addition, ovulation is often impaired as a result of systemic absorption of levonorgestrel.23 p. 162: Table 7-1. Myths and misconceptions about IUCs Myth: IUCs are abortifacients. Fact: IUCs prevent fertilization and are true contraceptives.
^ 54.054.154.2IUDs—An Update. Population Reports (Population Information Program, Johns Hopkins School of Public Health). December 1995, XXII (5).
^IUDs—An Update: Chapter 2.7: Expulsion. Population Reports (Population Information Program, Johns Hopkins School of Public Health). December 1995, XXII (5). (原始内容存档于2006-09-05).
^WHO Scientific Group on the Mechanism of Action Safety and Efficacy of Intrauterine Devices, World Health Organization. Mechanism of action, safety and efficacy of intrauterine devices. Geneva: World Health Organization. 1987. ISBN 92-4-120753-1. hdl:10665/38182. World Health Organization technical report series; no. 753.
^Bahamondes L, Hidalgo M, Petta CA, Diaz J, Espejo-Arce X, Monteiro-Dantas C. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. The Journal of Reproductive Medicine. August 2003, 48 (8): 637–640. PMID 12971147.
^Donders GG, Bellen G, Ruban K, Van Bulck B. Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and Candida. Journal of Medical Microbiology. March 2018, 67 (3): 308–313. PMID 29458551. doi:10.1099/jmm.0.000657.
^Nijhuis JG, Schijf CP, Eskes TK. [The lost IUD: don't look too far for it]. Nederlands Tijdschrift voor Geneeskunde. July 1985, 129 (30): 1409–1410. PMID 3900746.
^Kaplan NR. Letter: Lost IUD. Obstetrics and Gynecology. April 1976, 47 (4): 508–509. PMID 1256735.
^Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. The Journal of Family Planning and Reproductive Health Care. April 2004, 30 (2): 99–108; quiz 109. PMID 15086994. S2CID 31281104. doi:10.1783/147118904322995474.
^Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. The Australian & New Zealand Journal of Obstetrics & Gynaecology. June 2010, 50 (3): 273–279. PMID 20618247. S2CID 22050651. doi:10.1111/j.1479-828X.2010.01152.x.
^Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Human Reproduction. May 2010, 25 (5): 1158–1164. PMID 20185512. doi:10.1093/humrep/deq043.
^Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. June 2007, 75 (6 Suppl): S16–S30. PMID 17531610. doi:10.1016/j.contraception.2007.01.020. p. S28:
Conclusions 。Active substances released from the IUD or IUS, together with products derived from the inflammatory reaction present in the luminal fluids of the genital tract, are toxic for spermatozoa and oocytes, preventing the encounter of healthy gametes and the formation of viable embryos. The current data do not indicate that embryos are formed in IUD users at a rate comparable to that of nonusers. The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence. The bulk of the data indicate that interference with the reproductive process after fertilization has taken place is exceptional in the presence of a T-Cu or LNG-IUD and that the usual mechanism by which they prevent pregnancy in women is by preventing fertilization.
Mechanisms of action Thus, both clinical and experimental evidence suggests that IUDs can prevent and disrupt implantation. It is unlikely, however, that this is the main IUD mode of action, … The best evidence indicates that in IUD users it is unusual for embryos to reach the uterus. In conclusion, IUDs may exert their contraceptive action at different levels. Potentially, they interfere with sperm function and transport within the uterus and tubes. It is difficult to determine whether fertilization of the oocyte is impaired by these compromised sperm. There is sufficient evidence to suggest that IUDs can prevent and disrupt implantation. The extent to which this interference contributes to its contraceptive action is unknown. The data are scanty and the political consequences of resolving this issue interfere with comprehensive research. p. 205: Summary IUDs that release copper or levonorgestrel are extremely effective contraceptives... Both copper IUDs and levonorgestrel releasing IUSs may interfere with implantation, although this may not be the primary mechanism of action. The devices also create barriers to sperm transport and fertilization, and sensitive assays detect hCG in less than 1% of cycles, indicating that significant prevention must occur before the stage of implantation.
^Speroff L, Darney PD. Intrauterine contraception. A clinical guide for contraception 5th. Philadelphia: Lippincott Williams & Wilkins. 2011: 239–280. ISBN 978-1-60831-610-6. pp. 246–247:
Mechanism of action The contraceptive action of all IUDs is mainly in the intrauterine cavity. Ovulation is not affected, and the IUD is not an abortifacient.58–60 It is currently believed that the mechanism of action for IUDs is the production of an intrauterine environment that is spermicidal. Nonmedicated IUDs depend for contraception on the general reaction of the uterus to a foreign body. It is believed that this reaction, a sterile inflammatory response, produces tissue injury of a minor degree but sufficient to be spermicidal. Very few, if any, sperm reach the ovum in the fallopian tube. The progestin-releasing IUD adds the endometrial action of the progestin to the foreign body reaction. The endometrium becomes decidualized with atrophy of the glands.65 The progestin IUD probably has two mechanisms of action: inhibition of implantation and inhibition of sperm capacite journal, penetration, and survival.
^Jensen JT, Mishell Jr DR. Family planning: contraception, sterilization, and pregnancy termination.. Lentz GM, Lobo RA, Gershenson DM, Katz VL (编). Comprehensive gynecology. Philadelphia: Mosby Elsevier. 2012: 215–272. ISBN 978-0-323-06986-1. p. 259:
Intrauterine devices Mechanisms of action The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence... Because concern over mechanism of action represents a barrier to acceptance of this important and highly effective method for some women and some clinicians, it is important to point out that there is no evidence to suggest that the mechanism of action of IUDs is abortifacient. The LNG-IUS, like the copper device, has a very low ectopic pregnancy rate. Therefore, fertilization does not occur and its main mechanism of action is also preconceptual. Less inflammation occurs within the uterus of LNG-IUS users, but the potent progestin effect thickens cervical mucus to impede sperm penetration and access to the upper genital track.
^Thiery M. Intrauterine contraception: from silver ring to intrauterine contraceptive implant. European Journal of Obstetrics, Gynecology, and Reproductive Biology. June 2000, 90 (2): 145–152. PMID 10825633. doi:10.1016/s0301-2115(00)00262-1.